Bill proposes extension of patents for new uses of biologicals

Home/Policies & Legislation | Posted 04/04/2014 post-comment0 Post your comment

A new bill, introduced in the US House of Representatives on 24 March 2014, proposes allowing patent owners to extend terms for certain biological patents if they are approved for new indications.

Patent 1 V13E17

The legislation, entitled the Independent Innovator and Repurposing Act, is being co-sponsored by Representatives Joaquin Castro and Randy Forbes. The bill intends to incentivize research and development for new treatments by encouraging ‘independent innovators to pursue drug repurposing research and develop new treatments and cures by providing appropriate intellectual property protections for those innovations, and for other purposes’.

The bill would allow sponsors of biological products to extend patent terms on methods of using a biological product by five years from the original expiration date of the patent, including any patent term adjustment. This will, however, only apply when the product is approved for a new use and the sponsor is not affiliated with (or the same as) the original sponsor of the product.

Such an approach is already being used within industry and government by sharing compound libraries in order to screen for potentially useful compounds. However, this bill differs in that it focuses on already-approved products.

While the bill would apply to all future products, it would also be retroactive to all products approved in the last 10 years that meet its terms.

Related article

Representatives object to 7-year biologicals exclusivity

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: GovTrack, IProLife Sciences, RAPS

comment icon Comments (0)
Post your comment
Related content
Public consultation for the modification of the biosimilars regulation
02 AA010638
Home/Policies & Legislation Posted 16/01/2024
COFEPRIS promotes regulatory cooperation in the Americas
Latin America 1638px
Home/Policies & Legislation Posted 12/12/2023
ANVISA's decision on 'Skinny labels' for generics pending
Labelling V14I26
Home/Policies & Legislation Posted 14/11/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010